Shi Y - Search Results

1

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A. Frost P, et al. Among authors: shi y. Blood. 2004 Dec 15;104(13):4181-7. doi: 10.1182/blood-2004-03-1153. Epub 2004 Aug 10. Blood. 2004. PMID: 15304393 Free article.

2

The AKT kinase is activated in multiple myeloma tumor cells.

Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A. Hsu J, et al. Among authors: shi y. Blood. 2001 Nov 1;98(9):2853-5. doi: 10.1182/blood.v98.9.2853. Blood. 2001. PMID: 11675360 Free article.

3

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.

Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Hsu JH, et al. Among authors: shi y. Oncogene. 2002 Feb 21;21(9):1391-400. doi: 10.1038/sj.onc.1205194. Oncogene. 2002. PMID: 11857082

4

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A. Shi Y, et al. J Biol Chem. 2002 May 3;277(18):15712-20. doi: 10.1074/jbc.M200043200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872747 Free article.

5

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A. Shi Y, et al. Cancer Res. 2002 Sep 1;62(17):5027-34. Cancer Res. 2002. PMID: 12208757

6

Downstream effectors of oncogenic ras in multiple myeloma cells.

Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Hu L, et al. Among authors: shi y. Blood. 2003 Apr 15;101(8):3126-35. doi: 10.1182/blood-2002-08-2640. Epub 2002 Dec 19. Blood. 2003. PMID: 12515720 Free article.

7

Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.

Shi Y, Gera J, Hsu JH, Van Ness B, Lichtenstein A. Shi Y, et al. Mol Cancer Ther. 2003 Jun;2(6):563-72. Mol Cancer Ther. 2003. PMID: 12813136

8

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. Gera JF, et al. Among authors: shi y. J Biol Chem. 2004 Jan 23;279(4):2737-46. doi: 10.1074/jbc.M309999200. Epub 2003 Oct 23. J Biol Chem. 2004. PMID: 14576155 Free article.

9

Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways.

Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Hsu JH, et al. Among authors: shi y. Oncogene. 2004 Apr 22;23(19):3368-75. doi: 10.1038/sj.onc.1207459. Oncogene. 2004. PMID: 15021914

10

Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.

Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Shi Y, et al. J Biol Chem. 2005 Mar 25;280(12):10964-73. doi: 10.1074/jbc.M407874200. Epub 2005 Jan 4. J Biol Chem. 2005. PMID: 15634685 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34,376 results

Search Page

Filters